IMPORTANT CORRECTION OF DRUG INFORMATION

»Click here to review correction of information for TussiCaps®
Extended – Release Capsules CII in Response to July 2015 FDA Warning Letter.

2 Dosing Options

TussiCaps offers “full” and “half” dosage strengths1
  • One full-strength (10 mg/8 mg) capsule every 12 hours for patients 12 years of age and older1
  • One half-strength (5 mg/4 mg) capsule every 12 hours for patients 6 to 11 years of age1
  • Patients are not to exceed 2 capsules in a 24-hour period1
  • Do not use in children less than 6 years of age due to the risk of fatal respiratory depression1

Cost-Savings Offer*

Start Saving Today

*ELIGIBILITY AND RESTRICTIONS:By using the TussiCaps Savings Card, you confirm that you understand and agree to comply with the following terms and conditions of this offer. This offer is only valid for patients with commercial insurance. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan or any other federal or state health care programs. You agree not to seek reimbursement for all or any part of the benefit received through this offer and are responsible for making any required reports of your use of this offer to any insurer or other third party who pays any part of the prescription filled. This offer is good only in the United States of America (including the District of Columbia, Puerto Rico and the U.S. Virgin Islands) at participating retail pharmacies. You must be 18 years of age or older to redeem this offer for yourself or a minor. You must present the coupon along with your prescription to participate in this program. You must activate the coupon before using by calling 877-324-6175 or by visiting www.TussiCaps.com. The coupon is good for use only with the products identified herein. No other purchase is necessary. This offer cannot be redeemed at government-subsidized clinics. The coupon is good for a maximum of 5 prescription fills and has a maximum value per fill. You are responsible for paying $25 and any remaining amount over the maximum value. The coupon and offer are not health insurance. The selling, purchasing, trading, or counterfeiting of the coupon is prohibited by law. Void if reproduced. This offer is not valid with other offers. The coupon has no cash value. No cash back. Valeant Pharmaceuticals reserves the right to rescind, revoke, terminate, or amend this offer at any time, without notice. You understand and agree to comply with the terms and conditions of this offer as set forth above. This offer and coupon expire on 12/31/2016. For questions, please call 877-326-6367.

2 Dosing Options

TussiCaps offers “full” and “half” dosage strengths1
  • One full-strength (10 mg/8 mg) capsule every 12 hours for patients 12 years of age and older1
  • One half-strength (5 mg/4 mg) capsule every 12 hours for patients 6 to 11 years of age1
  • Patients are not to exceed 2 capsules in a 24-hour period1
  • Do not use in children less than 6 years of age due to the risk of fatal respiratory depression1

Cost-Savings Offer*

Start Saving Today

*ELIGIBILITY AND RESTRICTIONS:By using the TussiCaps Savings Card, you confirm that you understand and agree to comply with the following terms and conditions of this offer. This offer is only valid for patients with commercial insurance. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan or any other federal or state health care programs. You agree not to seek reimbursement for all or any part of the benefit received through this offer and are responsible for making any required reports of your use of this offer to any insurer or other third party who pays any part of the prescription filled. This offer is good only in the United States of America (including the District of Columbia, Puerto Rico and the U.S. Virgin Islands) at participating retail pharmacies. You must be 18 years of age or older to redeem this offer for yourself or a minor. You must present the coupon along with your prescription to participate in this program. You must activate the coupon before using by calling 877-324-6175 or by visiting www.TussiCaps.com. The coupon is good for use only with the products identified herein. No other purchase is necessary. This offer cannot be redeemed at government-subsidized clinics. The coupon is good for a maximum of 5 prescription fills and has a maximum value per fill. You are responsible for paying $25 and any remaining amount over the maximum value. The coupon and offer are not health insurance. The selling, purchasing, trading, or counterfeiting of the coupon is prohibited by law. Void if reproduced. This offer is not valid with other offers. The coupon has no cash value. No cash back. Valeant Pharmaceuticals reserves the right to rescind, revoke, terminate, or amend this offer at any time, without notice. You understand and agree to comply with the terms and conditions of this offer as set forth above. This offer and coupon expire on 12/31/2016. For questions, please call 877-326-6367.

INDICATION

TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.

IMPORTANT SAFETY INFORMATION
  • Do not use TussiCaps in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine.
  • Do not use in children less than 6 years of age due to the risk of fatal respiratory depression.
  • Because of the risk of respiratory depression, exercise caution when using TussiCaps postoperatively and in patients with pulmonary disease, or whenever ventilatory function is depressed. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.
  • The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Narcotics may produce adverse reactions which may obscure the clinical course of patients with head injuries.
  • The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
  • Chronic use of narcotics may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder.
  • Exercise caution when administering TussiCaps to pediatric patients 6 years of age and older. Overdose or concomitant administration of TussiCaps with other respiratory depressants may increase the risk of respiratory depression in pediatric patients.
  • Use with caution in elderly or debilitated patients and those with narrow-angle glaucoma, asthma, prostatic hypertrophy, severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, or urethral stricture.
  • Inform patients that TussiCaps may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  • Do not dilute with fluids or mix with other drugs as this may alter the resin-binding and change the absorption rate, possibly increasing the toxicity.
  • Use with caution when combined therapy includes narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with TussiCaps because patients may exhibit additive CNS depression.
  • The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus.
  • TussiCaps is a Schedule II narcotic and can be associated with drug abuse and dependence. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, TussiCaps extended-release capsules should be prescribed and administered with caution.
  • The following Adverse Events may occur:
    • o Nausea and vomiting
    • o Constipation
    • o Death
    • o Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, euphoria, dizziness, psychic dependence, mood changes
    • o Ureteral spasm, spasm of vesical sphincters, and urinary retention
    • o Dryness of the pharynx, occasional tightness of the chest, and respiratory depression
    • o Rash, pruritus
» Click here for full Prescribing Information.
References
  1. TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) Prescribing Information, Valeant Pharmaceuticals International, Inc; 2014.

INDICATION

TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.

IMPORTANT SAFETY INFORMATION
  • Do not use TussiCaps in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine.
  • Do not use in children less than 6 years of age due to the risk of fatal respiratory depression.
  • Because of the risk of respiratory depression, exercise caution when using TussiCaps postoperatively and in patients with pulmonary disease, or whenever ventilatory function is depressed. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.
  • The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Narcotics may produce adverse reactions which may obscure the clinical course of patients with head injuries.
  • The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
  • Chronic use of narcotics may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder.
  • Exercise caution when administering TussiCaps to pediatric patients 6 years of age and older. Overdose or concomitant administration of TussiCaps with other respiratory depressants may increase the risk of respiratory depression in pediatric patients.
  • Use with caution in elderly or debilitated patients and those with narrow-angle glaucoma, asthma, prostatic hypertrophy, severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, or urethral stricture.
  • Inform patients that TussiCaps may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  • Do not dilute with fluids or mix with other drugs as this may alter the resin-binding and change the absorption rate, possibly increasing the toxicity.
  • Use with caution when combined therapy includes narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with TussiCaps because patients may exhibit additive CNS depression.
  • The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus.
  • TussiCaps is a Schedule II narcotic and can be associated with drug abuse and dependence. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, TussiCaps extended-release capsules should be prescribed and administered with caution.
  • The following Adverse Events may occur:
    • o Nausea and vomiting
    • o Constipation
    • o Death
    • o Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, euphoria, dizziness, psychic dependence, mood changes
    • o Ureteral spasm, spasm of vesical sphincters, and urinary retention
    • o Dryness of the pharynx, occasional tightness of the chest, and respiratory depression
    • o Rash, pruritus
» Click here for full Prescribing Information.
INDICATION

TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.

IMPORTANT SAFETY INFORMATION
  • Do not use TussiCaps in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine.
  • Do not use in children less than 6 years of age due to the risk of fatal respiratory depression.
  • Because of the risk of respiratory depression, exercise caution when using TussiCaps postoperatively and in patients with pulmonary disease, or whenever ventilatory function is depressed. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.
  • The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Narcotics may produce adverse reactions which may obscure the clinical course of patients with head injuries.
  • The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
  • Chronic use of narcotics may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder.
  • Exercise caution when administering TussiCaps to pediatric patients 6 years of age and older. Overdose or concomitant administration of TussiCaps with other respiratory depressants may increase the risk of respiratory depression in pediatric patients.
  • Use with caution in elderly or debilitated patients and those with narrow-angle glaucoma, asthma, prostatic hypertrophy, severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, or urethral stricture.
  • Inform patients that TussiCaps may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  • Do not dilute with fluids or mix with other drugs as this may alter the resin-binding and change the absorption rate, possibly increasing the toxicity.
  • Use with caution when combined therapy includes narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with TussiCaps because patients may exhibit additive CNS depression.
  • The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus.
  • TussiCaps is a Schedule II narcotic and can be associated with drug abuse and dependence. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, TussiCaps extended-release capsules should be prescribed and administered with caution.
  • The following Adverse Events may occur:
    • o Nausea and vomiting
    • o Constipation
    • o Death
    • o Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, euphoria, dizziness, psychic dependence, mood changes
    • o Ureteral spasm, spasm of vesical sphincters, and urinary retention
    • o Dryness of the pharynx, occasional tightness of the chest, and respiratory depression
    • o Rash, pruritus
» Click here for full Prescribing Information.